INVO Fertility, Inc. Capitalized Contract Cost, Impairment Loss
INVO Fertility, Inc. (IVF) reported Capitalized Contract Cost, Impairment Loss of $1.40 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-06-02.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CapitalizedContractCostImpairmentLoss · last filed 2026-06-02
- INVO Fertility, Inc. capitalized contract cost, impairment loss for the quarter ending 2025-12-31 was $0.00.
- INVO Fertility, Inc. capitalized contract cost, impairment loss for the quarter ending 2025-09-30 was $0.00.
- INVO Fertility, Inc. capitalized contract cost, impairment loss for fiscal 2025 was $1.40M.
| Period end | Capitalized Contract Cost, Impairment Loss 3 month | Capitalized Contract Cost, Impairment Loss 6 month | Capitalized Contract Cost, Impairment Loss 9 month | Capitalized Contract Cost, Impairment Loss 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-02 | $0.00 derived: sum of 2 quarters · filed 2026-06-02 | $1.40M 10-K · filed 2026-06-02 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-17 | $1.40M 10-Q · filed 2025-11-17 | ||
| 2025-06-30 | $1.40M 10-Q · filed 2025-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Catheter Precision, Inc. (VTAK) | United States | $0.002B | -0.23 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| Tenon Medical, Inc. (TNON) | United States | $0.002B | |
| Profusa, Inc. (PFSA) | United States | $0.002B | |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B |